Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores.
J Clin Lab Anal
; 35(8): e23880, 2021 Aug.
Article
in English
| MEDLINE | ID: covidwho-1293190
ABSTRACT
BACKGROUND:
There is still little knowledge about the association of liver fibrosis with the clinical outcomes of COVID-19 patients with non-alcoholic fatty liver disease (NAFLD). The aim of the study was to determine the association of NAFLD fibrosis score (NFS)-determined liver fibrosis with clinical outcomes of COVID-19 patients with NAFLD.METHODS:
The NAFLD was diagnosed by the Hepatic Steatosis Index (HSI) in the absence of other causes of chronic liver diseases. NFS was used to evaluate the severity of liver fibrosis.RESULTS:
A total of 86 COVID-19 patients with NAFLD were included. The median age was 43.5 years, and 58.1% of patients were male. Thirty-eight (44.2%) patients had advanced liver fibrosis according to the NFS. Multivariate analysis indicated that concurrent diabetes (odds ratio [OR] 8.264, 95% confidence interval [CI] 1.202-56.830, p = 0.032) and advanced liver fibrosis (OR 11.057, 95% CI 1.193-102.439, p = 0.034) were independent risk factors of severe illness in COVID-19 patients with NAFLD.CONCLUSION:
NAFLD patients with NFS-determined advanced liver fibrosis are at higher risk of severe COVID-19.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Non-alcoholic Fatty Liver Disease
/
COVID-19
/
Liver Cirrhosis
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
J Clin Lab Anal
Journal subject:
Laboratory Techniques and procedures
Year:
2021
Document Type:
Article
Affiliation country:
Jcla.23880
Similar
MEDLINE
...
LILACS
LIS